Understanding how keratin 19 affects drug resistance in breast cancer
Characterizing Regulatory Mechanisms Underlying Drug Resistance in Breast Cancer Using Keratin 19
This study is looking at how a protein called keratin 19 affects breast cancer cells' ability to resist certain treatments, with the goal of finding better ways to personalize therapy for patients with advanced estrogen receptor-positive breast cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Catholic University of America NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10358875 on NIH RePORTER |
What this research studies
This research investigates the role of keratin 19, a cytoskeletal protein, in the resistance of breast cancer cells to CDK4/6 inhibitors, which are used to treat advanced estrogen receptor-positive tumors. The study aims to uncover the molecular mechanisms by which keratin 19 interacts with other proteins to influence cancer cell growth and drug sensitivity. By identifying how keratin 19 regulates these processes, the research seeks to develop predictive biomarkers that could help tailor more effective treatments for patients. The approach combines laboratory experiments with advanced biological assays to analyze the interactions and effects of keratin 19 in breast cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced estrogen receptor-positive breast cancer who are being treated with CDK4/6 inhibitors.
Not a fit: Patients with breast cancer who do not have estrogen receptor-positive tumors or are not receiving CDK4/6 inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for breast cancer patients by identifying biomarkers that predict drug resistance.
How similar studies have performed: Previous research has shown promising results in understanding drug resistance mechanisms in cancer, making this approach both relevant and potentially impactful.
Where this research is happening
Washington, United States
- Catholic University of America — Washington, United States (Active)
Researchers
- Principal investigator: Choy, John Sing — Catholic University of America
- Study coordinator: Choy, John Sing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.